Catalyst Event
Akeso Inc (9926) · Other
From Akros SCHK HK-Global Brain-Computer Interface Index (ASHGBCI)
5/29/2026, 12:00:00 AM
Akeso is scheduled to present Phase III HARMONi-6 study data for Ivonescimab at the ASCO Annual Meeting starting May 29, 2026. High importance is estimated as plenary session clinical data often drives significant price impact, scheduled.
Korean Translation
2026년 5월 29일 ASCO 연례회의에서 이보네시맙 임상 3상 데이터를 발표할 예정임. 본회의 세션 발표는 통상적으로 주가에 큰 영향을 미치므로 높은 중요도로 평가함, 예정됨.
Related Recent Events
Eli Lilly and Co (LLY) · Earnings Release
Q2 2026 earnings release and conference call. Medium importance is estimated as earnings releases typically cause >5% price volatility scheduled.
8/5/2026, 12:00:00 AM
Boston Scientific Corp (BSX) · Earnings Release
The Q2 2026 earnings release scheduled for 2026-07-29, for which high importance is estimated due to typical market volatility surrounding quarterly results, is expected.
7/29/2026, 12:00:00 AM
Abbott Laboratories (ABT) · Earnings Release
Q2 2026 earnings release is scheduled for July 16, 2026; a price impact of at least 5% is estimated based on historical volatility, scheduled.
7/16/2026, 12:00:00 AM
Hansoh Pharmaceutical Group Company Limited (3692) · Other
Final dividend of HKD 0.20 per share ex-dividend on July 3, 2026; standard corporate action with minor price adjustment scheduled.
7/3/2026, 12:00:00 AM
CSPC Pharmaceutical Group Ltd (1093) · Other
Ex-dividend date for the 2025 final dividend of HK$0.15 per share, which was announced on March 25, 2026. The payment date is July 15, 2026.
6/24/2026, 12:00:00 AM
Sonova Holding AG (SOON) · Other
Ex-dividend date (2026-06-19) for a proposed record-high annual dividend of CHF 4.70 per share; impact estimated at ~2% as dividend is record-high, scheduled.
6/19/2026, 12:00:00 AM